Ivacaftor (Kalydeco) appears safe and effective in treating cystic fibrosis in children under two and its early use may help preserve pancreatic function, according to results from a phase 3 trial involving two Australian centres. Currently listed on the PBS for CF treatment in children aged two to five, the results from the ARRIVAL trial ...
Ivacaftor ‘window of opportunity’ for CF treatment in children under two
By Michael Woodhead
19 Jun 2018